1. Pregnancy Outcomes and Child Development Effects of SARS-CoV-2 Infection (PROUDEST Trial): Protocol for a Multicenter, Prospective Cohort Study
- Author
-
Fernandes, Geraldo Magela, Motta, Felipe, Sasaki, Lizandra Moura Paravidine, Silva, Ângelo Pereira Da, Miranda, Andreza Monforte, Carvalho, Aleida Oliveira De, Gomides, Ana Paula Monteiro, Soares, Alexandre Anderson De Sousa Munhoz, Santos Jr, Agenor De Castro Moreira Dos, Alves, Caroline De Oliveira, Gomes, Ciro Martins, Siracusa, Clara Correia De, Araújo Jr, David Alves De, Mendonça-Silva, Dayde Lane, Jesus, José Alfredo Lacerda De, Costa, Karina Nascimento, Castro, Maria Eduarda Canellas De, Kurizky, Patricia Shu, França, Paulo Sérgio, Tristão, Rosana, Pereira, Yacara Ribeiro, Castro, Luiz Claudio Gonçalves De, Zaconeta, Alberto Moreno, Albuquerque, Cleandro Pires De, and Mota, Licia Maria Henrique Da
- Subjects
Medicine ,Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
BackgroundA growing body of evidence suggests that SARS-COV-2 infection during pregnancy may affect maternal-fetal outcomes and possibly result in implications for the long-term development of SARS-CoV-2–exposed children. ObjectiveThe PROUDEST (Pregnancy Outcomes and Child Development Effects of SARS-CoV-2 Infection Study) is a multicenter, prospective cohort study designed to elucidate the repercussions of COVID-19 for the global health of mothers and their children. MethodsThe PROUDEST trial comprises 2 prospective, sequential substudies. The PREGNANT substudy will clinically assess the effects of SARS-CoV-2 infection on pregnancy, childbirth, and puerperium from a mechanistic standpoint to elucidate the pregnancy-related inflammatory and immunological phenomena underlying COVID-19. Pregnant women aged 18-40 years who have been exposed (proven with laboratory tests) to SARS-CoV-2 (group A; n=300) will be compared to control subjects with no laboratory evidence of in-pregnancy exposure to the virus (group B; n=300). Subjects exposed to other infections during pregnancy will be excluded. The BORN substudy is a long-term follow-up study that will assess the offspring of women who enrolled in the prior substudy. It will describe the effects of SARS-CoV-2 exposure during pregnancy on children’s growth, neurodevelopment, and metabolism from birth up to 5 years of age. It includes two comparison groups; group A (exposed; n=300) comprises children born from SARS-CoV-2–exposed pregnancies, and group B (controls; n=300) comprises children born from nonexposed mothers. ResultsRecruitment began in July 2020, and as of January 2021, 260 pregnant women who were infected with SARS-CoV-2 during pregnancy and 160 newborns have been included in the study. Data analysis is scheduled to start after all data are collected. ConclusionsUpon completion of the study, we expect to have comprehensive data that will provide a better understanding of the effects of SARS-CoV-2 infection and related inflammatory and immunological processes on pregnancy, puerperium, and infancy. Our findings will inform clinical decisions regarding the care of SARS-CoV-2–exposed mothers and children and support the development of evidence-based public health policies. Trial RegistrationBrazilian Register of Clinical Trials RBR65QXS2; https://ensaiosclinicos.gov.br/rg/RBR-65qxs2 International Registered Report Identifier (IRRID)DERR1-10.2196/26477
- Published
- 2021
- Full Text
- View/download PDF